A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Clinical trial NCT00492297 · COMPLETED
Trial details
- NCT number
- NCT00492297
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-04-01
- Primary completion
- 2008-06-01
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.